Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain

Emerging Infectious Diseases

Volumn 15, Issue 6, 2009, Pages 905-911

  De La Campa, Adela G ^a,b,e   Ardanuy, Carmen ^b,c   Balsalobre, Luz ^a,b   Pérez Trallero, Emilio ^b,d   Marimón, Jose M ^b,d   Fenoll, Asunción ^a   Liñares, Josefina ^b,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital Universitary de Bellvitge   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; PROTEIN PARC; PROTEIN PARE; RESERPINE; TETRACYCLINE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFORMATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; SCHOOL CHILD; SEROTYPING; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMOCOCCAL VACCINES; PREVALENCE; SEQUENCE ANALYSIS, DNA; SEROTYPING; SPAIN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TRANSFORMATION, BACTERIAL; VACCINATION;

EID: 67449107299     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1506.080684     Document Type: Article

References (40)

1. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN; the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229-246 DOI: 10.1093/jac/dkg321
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72. DOI: 10.1086/511159 (Pubitemid 46290553)
3. Stanhope MJ, Walsh SL, Becker JA, Italia MJ, Ingraham KA, Gwynn MN, et al. Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread. Antimicrob Agents Chemother. 2005;49:4315-4326 DOI: 10.1128/AAC.49.10.4315-4326.2005
4. Balsalobre L, Ferrándiz MJ, Liñares J, Tubau F, de la Campa AG. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother. 2003;47:2072-2081 DOI: 10.1128/ AAC.47.7.2072-2081.2003
5. Bast DJ, de Azevedo JCS, Tam TY, Kilburn L, Duncan C, Mandell LA, et al. Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:2631-2634 DOI: 10.1128/AAC.45.9.2631-2634.2001
6. Yokota S, Sato K, Kuwahara O, Habadera S, Tsukamoto N, Ohuchi H, et al. Fluoroquinolone-resistant Streptococcus pneumoniae occurs frequently in elderly patients in Japan. Antimicrob Agents Chemother. 2002;46:3311-3315 DOI: 10.1128/AAC.46.10.3311-3315.2002
7. Ferrándiz MJ, Fenoll A, Liñares J, de la Campa AG. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000;44:840-847 DOI: 10.1128/AAC.44.4.840-847.2000
8. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42:2032-2035
9. Janoir C, Zeller V, Kitzis M-D, Moreau NJ, Gutmann L. Highlevel fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother. 1996;40:2760-2764 (Pubitemid 26404339)
10. Muñoz R, de la Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996;40:2252-2257
11. Tankovic J, Perichon B, Duval J, Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996;40:2505-2510
12. Pan X-S, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996;40:2321-2326
13. Fernández-Moreira E, Balas D, González I, de la Campa AG. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb Drug Resist. 2000;6:259-267 DOI: 10.1089/mdr.2000.6.259
14. Houssaye S, Gutmann L, Varon E. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46:2712-2715 DOI: 10.1128/AAC.46.8.2712-2715. 2002
15. de la Campa AG, Ferrándiz MJ, Tubau F, Pallarés R, Manresa F, Liñares J. Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob Agents Chemother. 2003;47:1419-1422 DOI: 10.1128/AAC.47.4.1419-1422.2003
16. Adam HJ, Schurek KN, Nichol KA, Hoban CJ, Baudry TJ, Laing NM, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother. 2007;51:198-207. DOI: 10.1128/AAC.00609-06
17. Morrissey I, Colclough A, Northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community- acquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Int J Antimicrob Agents. 2007;30:345-351 DOI: 10.1016/j.ijantimicag.2007.05.021
18. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lyn- field R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746 DOI: 10.1056/NEJMoa022823 (Pubitemid 36514704)
19. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-1463 DOI: 10.1056/NEJMoa051642
20. Beall B, McEllistrem MC, Gertz RE Jr, Wedel S, Boxrud DJ, González AL, et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol. 2006;44:999-1017. DOI: 10.1128/JCM.44.3.999- 1017.2006
21. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, García- García JJ, Pallarés R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182 DOI: 10.1086/524660 (Pubitemid 351269154)
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eighteenth informational supplement. CLSI document M100-S18. Wayne (PA): The Institute; 2008.
23. Ferrándiz MJ, Oteo J, Aracil B, Gómez-Garcés JL, de la Campa AG. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob Agents Chemother. 1999;43:2520-2523
24. de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Pérez-Trallero E, Liñares J. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis. 2004;10:1751-1759
25. Balsalobre L, de la Campa AG. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob Agents Chemother. 2008;52:822-830 DOI: 10.1128/AAC.00731-07
26. McGee L, McDougal L, Zhou J, Spratt BG, Tenover FC, George R, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol. 2001;39:2565-2571 DOI: 10.1128/JCM.39.7.2565-2571.2001
27. Tenover FC, Arbeit R, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-2239
28. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology. 1998;144:3049-3060
29. González I, Georgiou M, Alcaide F, Balas D, Liñares J, de la Campa AG. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother. 1998;42:2792-2798
30. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239 DOI: 10.1056/ NEJM199907223410403
31. Pérez-Trallero E, Marimón JM, Iglesias L, Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis. 2003;9:1159-1162 (Pubitemid 37071561)
32. Pérez-Trallero E, Marimón JM, González A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis. 2005;41:560-564 DOI: 10.1086/432062
33. de Cueto M, Rodríguez JM, Soriano MJ, López-Cerero L, Venero J, Pascual A. Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation. J Clin Microbiol. 2008;46:1558-1560 DOI: 10.1128/ JCM.02066-07 (Pubitemid 351563619)
34. Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother. 2005;49:2903-2913 DOI: 10.1128/ AAC.49.7.2903-2913.2005
35. Liñares J, de la Campa AG, Pallarés R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med. 1999;341:1546-1547 DOI: 10.1056/NEJM199911113412013
36. Pérez-Trallero E, García-Arenzana JM, Jiménez JA, Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1990;9:905-906 DOI: 10.1007/BF01967510
37. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-2051 DOI: 10.1001/ jama.294.16.2043 (Pubitemid 41539937)
38. Ardanuy C, Tubau F, Pallarés R, Calatayud L, Domínguez MA, Rolo D, et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent conjugate vaccine introduction, 1997-2007. Clin Infect Dis. 2009;48:57-64. DOI: 10.1086/594125
39. Murray TS, Baltimore RS. Pediatric uses of fluoroquinolone antibiotics. Pediatr Ann. 2007;36:336-342 (Pubitemid 46999773)
40. Rozen DE, McGee L, Levin BR, Klugman KP. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2007;51:412-416 DOI: 10.1128/AAC.01161-06